Recent data reveals that Cenobamate, a medication used in the treatment of epilepsy, significantly reduces seizure frequency and lowers overall health care utilization among patients. This promising development not only highlights Cenobamate’s efficacy in enhancing patient quality of life but also underscores its potential in reducing the risk of Sudden Unexpected Death in Epilepsy (SUDEP). The study found that patients treated with Cenobamate experienced a marked decrease in the number of hospital visits, thereby losing fewer workdays and reducing health care expenses. These outcomes may encourage healthcare providers to consider Cenobamate as a front-line option for epilepsy management. The reduced health care use, tied with the drug’s ability to minimize seizure incidents, positions Cenobamate as a groundbreaking treatment in the neurology field. Furthermore, the article emphasizes how innovations like Cenobamate can lead to both improved clinical outcomes and economic benefits, making it a considerable choice for patients and practitioners alike.
Neurology liveNew data shows Middle East Flight Chaos Affects Major Airports with Widespread Cancellations
March 4, 2026
Widespread flight cancellations have created significant disruptions at major airports across the Middle East, leaving travelers and airlines grappling with chaos. Key hubs like Doha,